Compare Bintang Mitra Semestaraya Tbk (BMSR) vs Brigit Biofarmaka Teknologi Tbk. (OBAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bintang Mitra Semestaraya Tbk vs Brigit Biofarmaka Teknologi Tbk. — how do they compare? Bintang Mitra Semestaraya Tbk trades at Rp302 (market cap 357.03B, 33.4K 24h volume), while Brigit Biofarmaka Teknologi Tbk. trades at Rp246 (market cap 167.37B, 71K 24h volume). The key difference: Bintang Mitra Semestaraya Tbk is far larger — about 2.1× Brigit Biofarmaka Teknologi Tbk.'s market cap, and Brigit Biofarmaka Teknologi Tbk. is more actively traded (71K versus 33.4K). Which is the better fit depends on your goals.
| BMSR | OBAT | |
|---|---|---|
Market Cap | 357.03B | 167.37B |
Volume | 33.4K | 71K |
Lot | 334 | 710 |
Turnover | 10.18M | 17.51M |
Average Price | 304.84 | 246.63 |
Value | 10.18M | 17.51M |
Indicative Equilibrium Price | 302 | 246 |
Indicative Equilibrium Volume | 4 | 1 |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bintang Mitra Semestaraya Tbk
PT Bintang Mitra Semestaraya Tbk (the Company) was established on November 16, 1989 based on Notarial Deed No. 240 of Mrs Siti Pertiwi Henny Shidki, S.H., which had been amended by Notarial Deed No. 246 dated May 31, 1991 by the same Notary regarding the change of name from PT Bintang Mahkota Semestaraya into PT Bintang Mitra Semestaraya. BMSR is a company that concentrate its business on investing its capital on property companies. It generally invest its capital through subsidiary companies and groups in developing commercial buildings, apartments and general housing.
Read more on BMSR →About Brigit Biofarmaka Teknologi Tbk.
PT. Brigit Biofarmaka Teknologi Tbk. (the Company) was established based on Notarial Deed No. 103 dated December 14, 2015 of Yoerista Arya Megasari, S.H., M.Kn., Notary in Sukoharjo. The company starts production commercially in 2018.
Read more on OBAT →
